Patent expirations to bring ultra-cheap Ozempic generics to Australia and global markets
Consensus Summary
The upcoming expiration of Ozempic’s patents in Australia in late 2029 and 2031 will drastically reduce its cost, mirroring trends already seen in India where generics cost as little as $20/month. This shift will make weight-loss drugs far more accessible to the estimated 500,000 Australians currently using them or unable to afford them. While the price drop is a boon for patients, it raises concerns about unintended social consequences, such as increased divorce rates among those undergoing rapid weight loss and the rise of 'Mounjaro bride' packages in India, where brides-to-be seek weight-loss drugs before weddings. Novo Nordisk, the drug’s manufacturer, faces declining stock prices due to generic competition but is investing in new formulations, including a pill version of Wegovy, to maintain market dominance. The broader societal impact may include a more isolated, health-focused population, as predicted by analysts like Derek Thompson.
✓ Verified by 2+ sources
Key details reported by multiple sources:
- Ozempic patents expire in Australia in late 2029 and again in 2031, allowing generics to enter the market
- Indian generic Ozempic costs 1290 rupees (~$20) per month for vial injections or 4500 rupees (~$55) for pen-style devices, compared to $299/month in Australia
- Novo Nordisk’s shares have dropped ~45% over the past 12 months to ~240 Danish Kroner ($54) due to generic competition
- Natco Pharma in India is offering a generic version of Ozempic
- A 2018 Swedish study found gastric band patients had a 14.4% divorce rate within 6 years vs. 8.2% in the general population
- Novo Nordisk is developing a pill version of Wegovy (Ozempic’s weight-loss brand) for Australian approval, which will take time to go generic
Points of Difference
Details reported by only one source:
- US writer Derek Thompson predicted a 'hot, high, and lonely' world in 2026 due to weight-loss drugs, cosmetic surgery, marijuana use, and social changes
- A Novo Nordisk spokeswoman stated: 'We are committed to serving patients around the world by not only meeting the demand for our existing treatments, but also by pioneering new innovations that enhance patient care.'
- The Business Briefing newsletter is mentioned as delivering major stories and expert opinion
- No additional unique details beyond SMH; identical content
Contradictions
Conflicting information between sources:
- Both sources are identical; no contradictions exist between SMH and THEAGE
Source Articles
Ultra-cheap Ozempic is coming. That’s a mixed blessing for Australians
Generic versions of the drug can cost as little as $20 a month overseas, in a glimpse of the future for Australia.
Ultra-cheap Ozempic is coming. That’s a mixed blessing for Australians
Generic versions of the drug can cost as little as $20 a month overseas, in a glimpse of the future for Australia.